220 related articles for article (PubMed ID: 32054769)
1. LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
Roberts MS; Sahni JM; Schrock MS; Piemonte KM; Weber-Bonk KL; Seachrist DD; Avril S; Anstine LJ; Singh S; Sizemore ST; Varadan V; Summers MK; Keri RA
Cancer Res; 2020 Apr; 80(8):1693-1706. PubMed ID: 32054769
[TBL] [Abstract][Full Text] [Related]
2. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
3. Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.
Sahni JM; Gayle SS; Webb BM; Weber-Bonk KL; Seachrist DD; Singh S; Sizemore ST; Restrepo NA; Bebek G; Scacheri PC; Varadan V; Summers MK; Keri RA
Cancer Res; 2017 Oct; 77(19):5395-5408. PubMed ID: 28807940
[TBL] [Abstract][Full Text] [Related]
4. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.
Giovinazzi S; Morozov VM; Summers MK; Reinhold WC; Ishov AM
Cell Death Differ; 2013 May; 20(5):721-31. PubMed ID: 23348568
[TBL] [Abstract][Full Text] [Related]
5. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
Lee J; Gollahon L
Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
[TBL] [Abstract][Full Text] [Related]
6. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death.
Fischer MM; Cancilla B; Yeung VP; Cattaruzza F; Chartier C; Murriel CL; Cain J; Tam R; Cheng CY; Evans JW; O'Young G; Song X; Lewicki J; Kapoun AM; Gurney A; Yen WC; Hoey T
Sci Adv; 2017 Jun; 3(6):e1700090. PubMed ID: 28691093
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
8. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
9. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
10. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Sprowl JA; Reed K; Armstrong SR; Lanner C; Guo B; Kalatskaya I; Stein L; Hembruff SL; Tam A; Parissenti AM
Breast Cancer Res; 2012 Jan; 14(1):R2. PubMed ID: 22225778
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
[TBL] [Abstract][Full Text] [Related]
12. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
Rodrigues-Ferreira S; Nehlig A; Moindjie H; Monchecourt C; Seiler C; Marangoni E; Chateau-Joubert S; Dujaric ME; Servant N; Asselain B; de Cremoux P; Lacroix-Triki M; Arnedos M; Pierga JY; André F; Nahmias C
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23691-23697. PubMed ID: 31685623
[TBL] [Abstract][Full Text] [Related]
13. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
[TBL] [Abstract][Full Text] [Related]
14. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
Chen C; Peng S; Li P; Ma L; Gan X
Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
[TBL] [Abstract][Full Text] [Related]
15. Targeting NEK2 as a promising therapeutic approach for cancer treatment.
Fang Y; Zhang X
Cell Cycle; 2016; 15(7):895-907. PubMed ID: 27019372
[TBL] [Abstract][Full Text] [Related]
16. Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity.
Fang Y; Kong Y; Xi J; Zhu M; Zhu T; Jiang T; Hu W; Ma M; Zhang X
Oncotarget; 2016 Nov; 7(48):79327-79341. PubMed ID: 27764815
[TBL] [Abstract][Full Text] [Related]
17. Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
Orth M; Unger K; Schoetz U; Belka C; Lauber K
Oncogene; 2018 Jan; 37(1):52-62. PubMed ID: 28869599
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Nek2 by small molecules affects proteasome activity.
Meng L; Carpenter K; Mollard A; Vankayalapati H; Warner SL; Sharma S; Tricot G; Zhan F; Bearss DJ
Biomed Res Int; 2014; 2014():273180. PubMed ID: 25313354
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
20. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
